Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 6/20 | 0.52 |
| ▸ | RAB9A | P51151 | 6/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.52 |
| ▸ | TP53 | P04637 | 2/20 | 0.52 |
| ▸ | HPGD | P15428 | 2/20 | 0.52 |
| ▸ | THRB | P10828 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.48 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.48 |
| ▸ | RELA | Q04206 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 3/20 | 0.47 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.47 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11959665 | 0.94 | NPC1 (0.49) | NPC1RAB9ASMN1; SMN2TP53HPGD | |
| SCHEMBL1868493 | 0.92 | NPC1 (0.61) | NPC1RAB9ASMN1; SMN2TP53HPGD | |
| SCHEMBL11959668 | 0.90 | NPC1 (0.49) | NPC1RAB9ASMN1; SMN2TP53HPGD | |
| SCHEMBL11959667 | 0.90 | PKM (0.49) | NPC1RAB9ASMN1; SMN2TP53HPGD | |
| SCHEMBL11959670 | 0.89 | NPC1 (0.50) | NPC1RAB9ASMN1; SMN2TP53HPGD | |
| SCHEMBL11959663 | 0.85 | NPC1 (0.47) | NPC1RAB9ASMN1; SMN2TP53HPGD | |
| SCHEMBL13061291 | 0.85 | NPC1 (0.50) | NPC1RAB9ASMN1; SMN2TP53HPGD | |
| SCHEMBL11959675 | 0.85 | NPC1 (0.48) | NPC1RAB9ASMN1; SMN2TP53HPGD | |
| SCHEMBL1858864 | 0.84 | PKM (0.47) | NPC1RAB9ASMN1; SMN2TP53HPGD | |
| SCHEMBL8244222 | 0.83 | NPC1 (0.57) | NPC1RAB9ASMN1; SMN2TP53HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8492403-B2 | Bicyclic derivatives as modulators of voltage gated ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-07-23 | — | — | US | disclosed |
| US-8492403-B2 | Bicyclic derivatives as modulators of voltage gated ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-07-23 | — | — | US | disclosed |
| US-8492403-B2 | Bicyclic derivatives as modulators of voltage gated ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-07-23 | — | — | US | disclosed |
| US-20130131109-A1 | BICYCLIC DERIVATIVES AS MODULATORS OF VOLTAGE GATED ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-05-23 | — | — | US | disclosed |
| US-20130131109-A1 | BICYCLIC DERIVATIVES AS MODULATORS OF VOLTAGE GATED ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-05-23 | — | — | US | disclosed |
| US-20130131109-A1 | BICYCLIC DERIVATIVES AS MODULATORS OF VOLTAGE GATED ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-05-23 | — | — | US | disclosed |
| US-8357702-B2 | Bicyclic derivatives as modulators of voltage gated ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-01-22 | — | — | US | disclosed |
| US-8357702-B2 | Bicyclic derivatives as modulators of voltage gated ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-01-22 | — | — | US | disclosed |
| US-8357702-B2 | Bicyclic derivatives as modulators of voltage gated ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-01-22 | — | — | US | disclosed |
| US-20120308606-A1 | BICYCLIC DERIVATIVES AS MODULATORS OF VOLTAGE GATED ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-12-06 | — | — | US | disclosed |
| US-20110112156-A1 | Bicyclic Derivatives as Modulators of Voltage Gated ION Channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-05-12 | — | — | US | disclosed |
| US-20110112156-A1 | Bicyclic Derivatives as Modulators of Voltage Gated ION Channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-05-12 | — | — | US | disclosed |
| US-20110112156-A1 | Bicyclic Derivatives as Modulators of Voltage Gated ION Channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-05-12 | — | — | US | disclosed |
| US-7855220-B2 | Bicyclic derivatives as modulators of voltage gated ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-12-21 | — | — | US | disclosed |
| US-7855220-B2 | Bicyclic derivatives as modulators of voltage gated ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-12-21 | — | — | US | disclosed |
| US-7855220-B2 | Bicyclic derivatives as modulators of voltage gated ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-12-21 | — | — | US | disclosed |
| US-20070203130-A1 | Bicyclic derivatives as modulators of voltage gated ion channels | VERTEX PHARMACEUTICALS INCORPORATED | 2007-08-30 | — | — | US | disclosed |
| US-20070203130-A1 | Bicyclic derivatives as modulators of voltage gated ion channels | VERTEX PHARMACEUTICALS INCORPORATED | 2007-08-30 | — | — | US | disclosed |
| US-20070203130-A1 | Bicyclic derivatives as modulators of voltage gated ion channels | VERTEX PHARMACEUTICALS INCORPORATED | 2007-08-30 | — | — | US | disclosed |
| WO-2007030618-A2 | BICYCLIC DERIVATIVES AS MODULATORS OF VOLTAGE GATED ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120308606-A1 | BICYCLIC DERIVATIVES AS MODULATORS OF VOLTAGE GATED ION CHANNELS | TRPV1, TRPV2, TRPV3 | NPC1 1196/4885RAB9A 1514/4885SMN1; SMN2 1855/4885 |
| US-20070203130-A1 | Bicyclic derivatives as modulators of voltage gated ion channels | TRPV1, TRPV2, TRPV3 | NPC1 1196/4885RAB9A 1514/4885SMN1; SMN2 1855/4885 |
| US-20130131109-A1 | BICYCLIC DERIVATIVES AS MODULATORS OF VOLTAGE GATED ION CHANNELS | TRPV1, TRPV2, TRPV3 | NPC1 1196/4885RAB9A 1514/4885SMN1; SMN2 1855/4885 |
| US-20110112156-A1 | Bicyclic Derivatives as Modulators of Voltage Gated ION Channels | TRPV1, TRPV2, TRPV3 | NPC1 1196/4885RAB9A 1514/4885SMN1; SMN2 1855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.